Georgiamune and Menarini Group enter global licensing agreement for GIM-621
Georgiamune has granted Menarini Group exclusive global rights to develop and commercialize GIM-621, an oral small-molecule immuno-oncology candidate.
Georgiamune and Menarini Group have announced a global licensing agreement for GIM-621, a preclinical small-molecule candidate designed for oral administration in oncology treatments. Under the terms of the deal, Menarini will take over the development and commercialization of the asset.
Georgiamune will receive $45 million in upfront and near-term payments. The agreement also includes potential milestone payments and tiered royalties based on future sales, providing the biotech firm with capital to advance its broader research pipeline.
GIM-621 targets solid tumors via an oral delivery mechanism, distinguishing it from many current injectable immunotherapies. The collaboration marks a significant transition for the candidate from the research phase to clinical development under the resources of a larger pharmaceutical entity.